Skip to main content

Table 2 Pulmonary function and 6-Minute-walk-distance characteristics of 10 patients with lymphangioleiomyomatosis

From: Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?

Pat. ID FEV1(l/% pred.) FVC (l/% pred.)
  Baseline 3 months p 6 months p baseline 3 months p 6 months p
1 1.79 62.0 1.39 49.0   2.22 77.6   2.65 77.4 2.75 81.4   3.17 93.2  
2 1.51 44.8 1.89 56.1   1.88 55.3   3.02 78.3 3.27 84.8   3.26 84.1  
3 1.69 44.3 1.86 48.7   1.98 51.9   2.90 66.1 2.99 67.3   3.12 71.4  
4 1.39 43.7 1.84 58.4   2.03 64.4   2.58 71.7 3.06 85.5   3.63 99.3  
5 0.34 12.3 0.53 19.1   0.64 23.3   0.78 24.9 1.58 49.6   1.54 48.1  
6 1.00 29.8 1.35 41.1   1.41 42.9   2.86 74.1 2.91 76.3   3.56 93.3  
7 0.93 34.4 1.22 45.1   1.11 41.3   3.17 99.0 2.99 94.2   2.99 94.2  
8 0.85 25.8 1.03 31.3   1.05 31.9   2.38 63.4 3.35 89.1   2.54 67.2  
9 0.95 27.6 1.22 41.6   1.30 44.4   2.98 88.5 2.94 86.4   3.18 94.2  
10 0.49 22.4 1.03 47.0   1.08 48.9   1.40 52.3 2.48 90.6   2.61 95.5  
Mean ± SEM 1.12 ± 0.15 36.1 ± 4.5 1.34 ± 0.14 44.0 ± 3.7 0.024 1.47 ± 0.17 48.1 ± 4.9 0.001 2.47 ± 0.25 69.2 ± 6.5 2.83 ± 0.16 80.2 ± 4.2 0.031 2.96 ± 0.19 83.9 ± 5.25 0.006